EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

MASLD Is Associated With an Increased Long‐Term Risk of Atrial Fibrillation: An Updated Systematic Review and Meta‐Analysis

Alessandro Mantovani iD, Riccardo Morandin, Elena Sani, Veronica Fiorio, Emigela Shtembari, Stefano Bonapace, Salvatore Petta iD, Stergios A Polyzos iD, Christopher D Byrne iD, Giovanni Targher iD

Liver International · 2025-01 · 45 (1)

DOI: 10.1111/liv.16218 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Liver International, online erschienen am 25.12.2024. Verfasst von Alessandro Mantovani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy. Hauptthemen laut MEDLINE: Atrial Fibrillation. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Studies have reported an association between metabolic dysfunction‐associated steatotic liver disease (MASLD) and an increased risk of developing atrial fibrillation (AF). However, the magnitude of the risk and whether this risk varies with the severity of MASLD remains uncertain.

Methods

In this systematic review and meta‐analysis, we searched three large electronic databases using predefined keywords to identify cohort studies (published up to 30 September 2024) in which MASLD was diagnosed by liver biopsy, imaging methods, International Classification of Diseases (ICD) codes, or blood‐based scores. The primary outcome was the occurrence of AF based on ICD codes, medical records, or electrocardiograms. Meta‐analysis was performed using random‐effects modelling.

Results

We identified 16 retrospective cohort studies with aggregate data on ~19.5 million individuals followed for a median of 7.2 years. MASLD was significantly associated with an increased risk of developing incident AF (random‐effects hazard ratio 1.20, 95% CI 1.10–1.32; I 2 = 92%). This risk did not appear to further increase with the severity of liver fibrosis ( n = 3 studies; random‐effects hazard ratio 1.22, 95% CI 1.18–1.26; I 2 = 10%). The risk of AF remained significant even after adjusting for age, sex, body mass index, hypertension, Type 2 diabetes or other cardiometabolic risk factors. Sensitivity analyses did not modify these findings. The funnel plot and Egger's test showed no significant publication bias.

Conclusions

This updated and comprehensive meta‐analysis provides evidence that MASLD is significantly associated with an increased long‐term risk of developing incident AF. Further research is required to better decipher the link between MASLD and increased AF incidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationHumansRisk FactorsFatty LiverFemaleMaleIncidenceRisk Assessment

Stichwörter der Autor:innen

MASLDNAFLDarrhythmiasatrial fibrillationmetabolic dysfunction‐associated steatotic liver diseasenon‐alcoholic fatty liver disease

Autor:innen und Institutionen

  • Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy.
  • Division of Cardiology, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella, Negrar, Italy.
  • Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy.
  • First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • National Institute for Health and Care Research, Southampton Biomedical Research Centre, University Hospital Southampton and University of Southampton, Southampton, UK.
  • Department of Medicine, University of Verona, Verona, Italy.

ORCID-Profile: Alessandro Mantovani, Salvatore Petta, Stergios A Polyzos, Christopher D Byrne, Giovanni Targher

Zitieren

APA

Mantovani, A., Morandin, R., Sani, E., Fiorio, V., Shtembari, E., Bonapace, S., Petta, S., Polyzos, S. A., Byrne, C. D., & Targher, G. (2025). MASLD Is Associated With an Increased Long‐Term Risk of Atrial Fibrillation: An Updated Systematic Review and Meta‐Analysis. Liver International, 45(1). https://doi.org/10.1111/liv.16218

Vancouver

Mantovani A, Morandin R, Sani E, Fiorio V, Shtembari E, Bonapace S, et al. MASLD Is Associated With an Increased Long‐Term Risk of Atrial Fibrillation: An Updated Systematic Review and Meta‐Analysis. Liver International. 2025;45(1). doi:10.1111/liv.16218

BibTeX
@article{Mantovani2025,
  author = {Mantovani, Alessandro and Morandin, Riccardo and Sani, Elena and Fiorio, Veronica and Shtembari, Emigela and Bonapace, Stefano and Petta, Salvatore and Polyzos, Stergios A and Byrne, Christopher D and Targher, Giovanni},
  title = {MASLD Is Associated With an Increased Long‐Term Risk of Atrial Fibrillation: An Updated Systematic Review and Meta‐Analysis},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {1},
  doi = {10.1111/liv.16218}
}
Kostenlos starten →